Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 124, Issue 4, Pages 1794-1809
Publisher
American Society for Clinical Investigation
Online
2014-02-26
DOI
10.1172/jci69927
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
- (2013) Pascal Furet et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway
- (2012) Ian Bruce et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting oncogenic Ras signaling in hematologic malignancies
- (2012) A. F. Ward et al. BLOOD
- Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
- (2012) Irene Brana et al. BMC Medicine
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Selective small molecule inhibitors of p110α and δ isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors
- (2012) Yan Xing et al. EXPERIMENTAL HEMATOLOGY
- The p110 and p110 isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis
- (2012) T. Utermark et al. GENES & DEVELOPMENT
- Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk
- (2012) Karl Staser et al. JOURNAL OF CLINICAL INVESTIGATION
- Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice
- (2012) Tiffany Chang et al. JOURNAL OF CLINICAL INVESTIGATION
- DNA Methylation As a Clinical Marker in Oncology
- (2012) Jean-Pierre Issa JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
- (2012) Jay P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia
- (2011) R. Polak et al. BLOOD
- Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
- (2011) D. Koul et al. CLINICAL CANCER RESEARCH
- A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice
- (2011) N. Lyubynska et al. Science Translational Medicine
- AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species
- (2010) M. M. Juntilla et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways
- (2009) M. Rahmani et al. BLOOD
- Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice
- (2009) M. G. Kharas et al. BLOOD
- Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
- (2009) Claudia Scholl et al. CELL
- Should individual PI3 kinase isoforms be targeted in cancer?
- (2009) Shidong Jia et al. CURRENT OPINION IN CELL BIOLOGY
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
- (2009) M. L. Sos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species
- (2008) Chong Chen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started